Pay-for-delay: Play by the rules

On September 8, the EU General Court handed down its judgment in appeal proceedings brought by Danish innovator Lundbeck and a number of generic companies against a 2013 European Commission decision that imposed fines of €146 million ($164 million) on the appellants.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Beyond the primary patent: How pharma can build competitive barriers

16 September 2026 A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.

Pharma

J&J unit win shuts door on Sandoz generic launch

10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.

Pharma

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.

More features

Beyond the primary patent: How pharma can build competitive barriers

Patent lawyers and judges discuss lofty UPC issues in grand London venue

J&J unit win shuts door on Sandoz generic launch

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

10x Genomics wins latest round in Parse patent dispute

Teva faces scrutiny over efforts to curb generic competition

FDA targets faster generic approvals in drive to slash drug prices

The buyers' wishlist: What makes a life sciences deal stack up?

Pay-for-delay: Play by the rules

More on this story

Editor's picks

Editor's picks

More features